Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
14.80
-0.09 (-0.60%)
Nov 20, 2026, 12:03 PM EST - Market open
Aurinia Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 321.74 | 283.06 | 235.13 | 175.51 | 134.03 | 45.61 | |
Revenue Growth | 21.04% | 20.38% | 33.97% | 30.95% | 193.89% | -9.01% |
Cost of Revenue | 78.19 | 65.17 | 49.03 | 63.79 | 50.65 | 52.23 |
Gross Profit | 243.55 | 217.89 | 186.1 | 111.72 | 83.38 | -6.63 |
Selling, General & Admin | 99.48 | 101.79 | 172.03 | 195.04 | 196.37 | 173.54 |
Other Operating Expenses | -22 | -0.17 | 1.55 | 2.48 | -1.52 | 0.57 |
Operating Expenses | 77.48 | 101.62 | 173.58 | 197.52 | 194.85 | 174.11 |
Operating Income | 166.07 | 116.26 | 12.52 | -85.79 | -111.47 | -180.74 |
Interest Expense | -3.87 | -4.33 | -4.84 | -2.78 | - | - |
Interest & Investment Income | 14.63 | 13.57 | 16.97 | 17 | 5.12 | 0.53 |
Currency Exchange Gain (Loss) | -9.7 | -9.7 | 5.9 | -5.9 | - | - |
EBT Excluding Unusual Items | 167.12 | 115.8 | 30.55 | -77.47 | -106.35 | -180.21 |
Merger & Restructuring Charges | - | -1.65 | -23.11 | - | - | - |
Pretax Income | 167.12 | 114.16 | 7.45 | -77.47 | -106.35 | -180.21 |
Income Tax Expense | -147.15 | -173.05 | 1.7 | 0.55 | 1.83 | 0.76 |
Net Income | 314.27 | 287.2 | 5.75 | -78.02 | -108.18 | -180.97 |
Net Income to Common | 314.27 | 287.2 | 5.75 | -78.02 | -108.18 | -180.97 |
Net Income Growth | 303.75% | 4893.08% | - | - | - | - |
Shares Outstanding (Basic) | 132 | 134 | 143 | 143 | 142 | 129 |
Shares Outstanding (Diluted) | 136 | 139 | 146 | 143 | 142 | 129 |
Shares Change | -4.00% | -5.13% | 2.07% | 0.93% | 9.70% | 9.20% |
EPS (Basic) | 2.38 | 2.14 | 0.04 | -0.54 | -0.76 | -1.40 |
EPS (Diluted) | 2.31 | 2.07 | 0.04 | -0.54 | -0.76 | -1.40 |
EPS Growth | 319.13% | 5075.00% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 177.03 | 135.41 | 44.11 | -34.18 | -79.82 | -158 |
Free Cash Flow Per Share | 1.30 | 0.98 | 0.30 | -0.24 | -0.56 | -1.22 |
Gross Margin | 75.70% | 76.98% | 79.15% | 63.66% | 62.21% | -14.53% |
Operating Margin | 51.62% | 41.07% | 5.32% | -48.88% | -83.17% | -396.31% |
Profit Margin | 97.68% | 101.47% | 2.45% | -44.45% | -80.71% | -396.81% |
Free Cash Flow Margin | 55.02% | 47.84% | 18.76% | -19.47% | -59.55% | -346.44% |
EBITDA | 185.42 | 135.71 | 31.96 | -74.14 | -108.76 | -177.97 |
EBITDA Margin | 57.63% | 47.95% | 13.59% | -42.24% | -81.15% | - |
D&A For EBITDA | 19.36 | 19.45 | 19.45 | 11.65 | 2.71 | 2.76 |
EBIT | 166.07 | 116.26 | 12.52 | -85.79 | -111.47 | -180.74 |
EBIT Margin | 51.62% | 41.07% | 5.32% | -48.88% | -83.17% | - |
Effective Tax Rate | - | - | 22.77% | - | - | - |
Revenue as Reported | 321.74 | 283.06 | 235.13 | 175.51 | 134.03 | 45.61 |